Stemline Therapeutics Inc (NASDAQ:STML) Expected to Announce Earnings of -$0.49 Per Share
Equities research analysts expect that Stemline Therapeutics Inc (NASDAQ:STML) will announce earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.54) to ($0.38). Stemline Therapeutics posted earnings of ($0.66) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 25.8%. The firm is scheduled to report its next earnings report on Thursday, August 8th.
On average, analysts expect that Stemline Therapeutics will report full-year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.55). For the next year, analysts anticipate that the firm will post earnings of $0.29 per share, with EPS estimates ranging from ($1.25) to $2.12. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million.
In related news, COO Kenneth Hoberman sold 25,817 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total transaction of $368,408.59. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 14.80% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Rubric Capital Management LP acquired a new stake in Stemline Therapeutics in the first quarter valued at approximately $38,614,000. BlackRock Inc. boosted its stake in shares of Stemline Therapeutics by 30.9% in the 1st quarter. BlackRock Inc. now owns 2,703,489 shares of the biopharmaceutical company’s stock valued at $34,740,000 after purchasing an additional 638,250 shares in the last quarter. Polar Capital LLP boosted its stake in shares of Stemline Therapeutics by 12.1% in the 4th quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock valued at $21,875,000 after purchasing an additional 248,616 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Stemline Therapeutics by 3,363.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,363,968 shares of the biopharmaceutical company’s stock valued at $17,527,000 after purchasing an additional 1,324,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after purchasing an additional 18,487 shares in the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.
Shares of STML traded down $0.13 during mid-day trading on Wednesday, hitting $13.29. 296,805 shares of the company’s stock were exchanged, compared to its average volume of 631,847. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $18.15. The stock has a market capitalization of $586.25 million, a PE ratio of -4.44 and a beta of 1.25. The company has a current ratio of 5.07, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Article: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.